Table of Content

1 Study Coverage
1.1 Vaccine Conjugate Product Introduction
1.2 Market by Type
1.2.1 Global Vaccine Conjugate Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Hib Vaccine
1.2.3 Meningococcal Vaccine
1.2.4 Pneumococcal Vaccine
1.2.5 Others
1.3 Market by Application
1.3.1 Global Vaccine Conjugate Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Children
1.3.3 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Vaccine Conjugate Sales Estimates and Forecasts 2018-2029
2.2 Global Vaccine Conjugate Revenue by Region
2.2.1 Global Vaccine Conjugate Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Vaccine Conjugate Revenue by Region (2018-2024)
2.2.3 Global Vaccine Conjugate Revenue by Region (2024-2029)
2.2.4 Global Vaccine Conjugate Revenue Market Share by Region (2018-2029)
2.3 Global Vaccine Conjugate Sales Estimates and Forecasts 2018-2029
2.4 Global Vaccine Conjugate Sales by Region
2.4.1 Global Vaccine Conjugate Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Vaccine Conjugate Sales by Region (2018-2024)
2.4.3 Global Vaccine Conjugate Sales by Region (2024-2029)
2.4.4 Global Vaccine Conjugate Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Vaccine Conjugate Sales by Manufacturers
3.1.1 Global Vaccine Conjugate Sales by Manufacturers (2018-2024)
3.1.2 Global Vaccine Conjugate Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaccine Conjugate in 2022
3.2 Global Vaccine Conjugate Revenue by Manufacturers
3.2.1 Global Vaccine Conjugate Revenue by Manufacturers (2018-2024)
3.2.2 Global Vaccine Conjugate Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaccine Conjugate Revenue in 2022
3.3 Global Key Players of Vaccine Conjugate, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Vaccine Conjugate Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaccine Conjugate Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaccine Conjugate, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaccine Conjugate, Product Offered and Application
3.8 Global Key Manufacturers of Vaccine Conjugate, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaccine Conjugate Sales by Type
4.1.1 Global Vaccine Conjugate Historical Sales by Type (2018-2024)
4.1.2 Global Vaccine Conjugate Forecasted Sales by Type (2024-2029)
4.1.3 Global Vaccine Conjugate Sales Market Share by Type (2018-2029)
4.2 Global Vaccine Conjugate Revenue by Type
4.2.1 Global Vaccine Conjugate Historical Revenue by Type (2018-2024)
4.2.2 Global Vaccine Conjugate Forecasted Revenue by Type (2024-2029)
4.2.3 Global Vaccine Conjugate Revenue Market Share by Type (2018-2029)
4.3 Global Vaccine Conjugate Price by Type
4.3.1 Global Vaccine Conjugate Price by Type (2018-2024)
4.3.2 Global Vaccine Conjugate Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Vaccine Conjugate Sales by Application
5.1.1 Global Vaccine Conjugate Historical Sales by Application (2018-2024)
5.1.2 Global Vaccine Conjugate Forecasted Sales by Application (2024-2029)
5.1.3 Global Vaccine Conjugate Sales Market Share by Application (2018-2029)
5.2 Global Vaccine Conjugate Revenue by Application
5.2.1 Global Vaccine Conjugate Historical Revenue by Application (2018-2024)
5.2.2 Global Vaccine Conjugate Forecasted Revenue by Application (2024-2029)
5.2.3 Global Vaccine Conjugate Revenue Market Share by Application (2018-2029)
5.3 Global Vaccine Conjugate Price by Application
5.3.1 Global Vaccine Conjugate Price by Application (2018-2024)
5.3.2 Global Vaccine Conjugate Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Vaccine Conjugate Market Size by Type
6.1.1 US & Canada Vaccine Conjugate Sales by Type (2018-2029)
6.1.2 US & Canada Vaccine Conjugate Revenue by Type (2018-2029)
6.2 US & Canada Vaccine Conjugate Market Size by Application
6.2.1 US & Canada Vaccine Conjugate Sales by Application (2018-2029)
6.2.2 US & Canada Vaccine Conjugate Revenue by Application (2018-2029)
6.3 US & Canada Vaccine Conjugate Market Size by Country
6.3.1 US & Canada Vaccine Conjugate Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Vaccine Conjugate Sales by Country (2018-2029)
6.3.3 US & Canada Vaccine Conjugate Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Vaccine Conjugate Market Size by Type
7.1.1 Europe Vaccine Conjugate Sales by Type (2018-2029)
7.1.2 Europe Vaccine Conjugate Revenue by Type (2018-2029)
7.2 Europe Vaccine Conjugate Market Size by Application
7.2.1 Europe Vaccine Conjugate Sales by Application (2018-2029)
7.2.2 Europe Vaccine Conjugate Revenue by Application (2018-2029)
7.3 Europe Vaccine Conjugate Market Size by Country
7.3.1 Europe Vaccine Conjugate Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Vaccine Conjugate Sales by Country (2018-2029)
7.3.3 Europe Vaccine Conjugate Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Vaccine Conjugate Market Size
8.1.1 China Vaccine Conjugate Sales (2018-2029)
8.1.2 China Vaccine Conjugate Revenue (2018-2029)
8.2 China Vaccine Conjugate Market Size by Application
8.2.1 China Vaccine Conjugate Sales by Application (2018-2029)
8.2.2 China Vaccine Conjugate Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Vaccine Conjugate Market Size by Type
9.1.1 Asia Vaccine Conjugate Sales by Type (2018-2029)
9.1.2 Asia Vaccine Conjugate Revenue by Type (2018-2029)
9.2 Asia Vaccine Conjugate Market Size by Application
9.2.1 Asia Vaccine Conjugate Sales by Application (2018-2029)
9.2.2 Asia Vaccine Conjugate Revenue by Application (2018-2029)
9.3 Asia Vaccine Conjugate Sales by Region
9.3.1 Asia Vaccine Conjugate Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Vaccine Conjugate Revenue by Region (2018-2029)
9.3.3 Asia Vaccine Conjugate Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaccine Conjugate Market Size by Type
10.1.1 Middle East, Africa and Latin America Vaccine Conjugate Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Vaccine Conjugate Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Vaccine Conjugate Market Size by Application
10.2.1 Middle East, Africa and Latin America Vaccine Conjugate Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Vaccine Conjugate Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Vaccine Conjugate Sales by Country
10.3.1 Middle East, Africa and Latin America Vaccine Conjugate Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Vaccine Conjugate Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Vaccine Conjugate Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Pfizer Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 GSK Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Sanofi Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Merck
11.4.1 Merck Company Information
11.4.2 Merck Overview
11.4.3 Merck Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Merck Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Walvax Biotechnology
11.5.1 Walvax Biotechnology Company Information
11.5.2 Walvax Biotechnology Overview
11.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Walvax Biotechnology Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Walvax Biotechnology Recent Developments
11.6 Royal (Wuxi) Bio-Pharmaceutical
11.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
11.6.2 Royal (Wuxi) Bio-Pharmaceutical Overview
11.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
11.7 Bharat Biotech
11.7.1 Bharat Biotech Company Information
11.7.2 Bharat Biotech Overview
11.7.3 Bharat Biotech Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Bharat Biotech Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bharat Biotech Recent Developments
11.8 Zhifei Biologic
11.8.1 Zhifei Biologic Company Information
11.8.2 Zhifei Biologic Overview
11.8.3 Zhifei Biologic Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Zhifei Biologic Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Zhifei Biologic Recent Developments
11.9 Chengdu Olymvax Biopharmaceuticals
11.9.1 Chengdu Olymvax Biopharmaceuticals Company Information
11.9.2 Chengdu Olymvax Biopharmaceuticals Overview
11.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
11.10 Beijing Minhai Biotechnology
11.10.1 Beijing Minhai Biotechnology Company Information
11.10.2 Beijing Minhai Biotechnology Overview
11.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Beijing Minhai Biotechnology Recent Developments
11.11 CanSinoBIO
11.11.1 CanSinoBIO Company Information
11.11.2 CanSinoBIO Overview
11.11.3 CanSinoBIO Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 CanSinoBIO Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 CanSinoBIO Recent Developments
11.12 Beijing Xiangrui Biological Products
11.12.1 Beijing Xiangrui Biological Products Company Information
11.12.2 Beijing Xiangrui Biological Products Overview
11.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Beijing Xiangrui Biological Products Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaccine Conjugate Industry Chain Analysis
12.2 Vaccine Conjugate Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine Conjugate Production Mode & Process
12.4 Vaccine Conjugate Sales and Marketing
12.4.1 Vaccine Conjugate Sales Channels
12.4.2 Vaccine Conjugate Distributors
12.5 Vaccine Conjugate Customers
13 Market Dynamics
13.1 Vaccine Conjugate Industry Trends
13.2 Vaccine Conjugate Market Drivers
13.3 Vaccine Conjugate Market Challenges
13.4 Vaccine Conjugate Market Restraints
14 Key Findings in The Global Vaccine Conjugate Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vaccine Conjugate Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Hib Vaccine
Table 3. Major Manufacturers of Meningococcal Vaccine
Table 4. Major Manufacturers of Pneumococcal Vaccine
Table 5. Major Manufacturers of Others
Table 6. Global Vaccine Conjugate Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Vaccine Conjugate Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Vaccine Conjugate Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Vaccine Conjugate Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Vaccine Conjugate Revenue Market Share by Region (2018-2024)
Table 11. Global Vaccine Conjugate Revenue Market Share by Region (2024-2029)
Table 12. Global Vaccine Conjugate Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Vaccine Conjugate Sales by Region (2018-2024) & (K Doses)
Table 14. Global Vaccine Conjugate Sales by Region (2024-2029) & (K Doses)
Table 15. Global Vaccine Conjugate Sales Market Share by Region (2018-2024)
Table 16. Global Vaccine Conjugate Sales Market Share by Region (2024-2029)
Table 17. Global Vaccine Conjugate Sales by Manufacturers (2018-2024) & (K Doses)
Table 18. Global Vaccine Conjugate Sales Share by Manufacturers (2018-2024)
Table 19. Global Vaccine Conjugate Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Vaccine Conjugate Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Vaccine Conjugate, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Vaccine Conjugate Price by Manufacturers 2018-2024 (US$/Dose)
Table 23. Global Vaccine Conjugate Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Vaccine Conjugate by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine Conjugate as of 2022)
Table 25. Global Key Manufacturers of Vaccine Conjugate, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Vaccine Conjugate, Product Offered and Application
Table 27. Global Key Manufacturers of Vaccine Conjugate, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 30. Global Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 31. Global Vaccine Conjugate Sales Share by Type (2018-2024)
Table 32. Global Vaccine Conjugate Sales Share by Type (2024-2029)
Table 33. Global Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Vaccine Conjugate Revenue Share by Type (2018-2024)
Table 36. Global Vaccine Conjugate Revenue Share by Type (2024-2029)
Table 37. Vaccine Conjugate Price by Type (2018-2024) & (US$/Dose)
Table 38. Global Vaccine Conjugate Price Forecast by Type (2024-2029) & (US$/Dose)
Table 39. Global Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 40. Global Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 41. Global Vaccine Conjugate Sales Share by Application (2018-2024)
Table 42. Global Vaccine Conjugate Sales Share by Application (2024-2029)
Table 43. Global Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Vaccine Conjugate Revenue Share by Application (2018-2024)
Table 46. Global Vaccine Conjugate Revenue Share by Application (2024-2029)
Table 47. Vaccine Conjugate Price by Application (2018-2024) & (US$/Dose)
Table 48. Global Vaccine Conjugate Price Forecast by Application (2024-2029) & (US$/Dose)
Table 49. US & Canada Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 50. US & Canada Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 51. US & Canada Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 54. US & Canada Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 55. US & Canada Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Vaccine Conjugate Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Vaccine Conjugate Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Vaccine Conjugate Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 61. US & Canada Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 62. Europe Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 63. Europe Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 64. Europe Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 67. Europe Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 68. Europe Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Vaccine Conjugate Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Vaccine Conjugate Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Vaccine Conjugate Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 74. Europe Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 75. China Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 76. China Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 77. China Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 80. China Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 81. China Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 84. Asia Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 85. Asia Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 88. Asia Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 89. Asia Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Vaccine Conjugate Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Vaccine Conjugate Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Vaccine Conjugate Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Vaccine Conjugate Sales by Region (2018-2024) & (K Doses)
Table 95. Asia Vaccine Conjugate Sales by Region (2024-2029) & (K Doses)
Table 96. Middle East, Africa and Latin America Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 97. Middle East, Africa and Latin America Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 98. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 101. Middle East, Africa and Latin America Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 102. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Vaccine Conjugate Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Vaccine Conjugate Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 108. Middle East, Africa and Latin America Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 109. Pfizer Company Information
Table 110. Pfizer Description and Major Businesses
Table 111. Pfizer Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 112. Pfizer Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Pfizer Recent Developments
Table 114. GSK Company Information
Table 115. GSK Description and Major Businesses
Table 116. GSK Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 117. GSK Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. GSK Recent Developments
Table 119. Sanofi Company Information
Table 120. Sanofi Description and Major Businesses
Table 121. Sanofi Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 122. Sanofi Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Sanofi Recent Developments
Table 124. Merck Company Information
Table 125. Merck Description and Major Businesses
Table 126. Merck Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 127. Merck Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Merck Recent Developments
Table 129. Walvax Biotechnology Company Information
Table 130. Walvax Biotechnology Description and Major Businesses
Table 131. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 132. Walvax Biotechnology Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Walvax Biotechnology Recent Developments
Table 134. Royal (Wuxi) Bio-Pharmaceutical Company Information
Table 135. Royal (Wuxi) Bio-Pharmaceutical Description and Major Businesses
Table 136. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 137. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Royal (Wuxi) Bio-Pharmaceutical Recent Developments
Table 139. Bharat Biotech Company Information
Table 140. Bharat Biotech Description and Major Businesses
Table 141. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 142. Bharat Biotech Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Bharat Biotech Recent Developments
Table 144. Zhifei Biologic Company Information
Table 145. Zhifei Biologic Description and Major Businesses
Table 146. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 147. Zhifei Biologic Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Zhifei Biologic Recent Developments
Table 149. Chengdu Olymvax Biopharmaceuticals Company Information
Table 150. Chengdu Olymvax Biopharmaceuticals Description and Major Businesses
Table 151. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 152. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Chengdu Olymvax Biopharmaceuticals Recent Developments
Table 154. Beijing Minhai Biotechnology Company Information
Table 155. Beijing Minhai Biotechnology Description and Major Businesses
Table 156. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 157. Beijing Minhai Biotechnology Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Beijing Minhai Biotechnology Recent Developments
Table 159. CanSinoBIO Company Information
Table 160. CanSinoBIO Description and Major Businesses
Table 161. CanSinoBIO Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 162. CanSinoBIO Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. CanSinoBIO Recent Developments
Table 164. Beijing Xiangrui Biological Products Company Information
Table 165. Beijing Xiangrui Biological Products Description and Major Businesses
Table 166. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 167. Beijing Xiangrui Biological Products Vaccine Conjugate Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. Beijing Xiangrui Biological Products Recent Developments
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Vaccine Conjugate Distributors List
Table 172. Vaccine Conjugate Customers List
Table 173. Vaccine Conjugate Market Trends
Table 174. Vaccine Conjugate Market Drivers
Table 175. Vaccine Conjugate Market Challenges
Table 176. Vaccine Conjugate Market Restraints
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine Conjugate Product Picture
Figure 2. Global Vaccine Conjugate Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Vaccine Conjugate Market Share by Type in 2022 & 2029
Figure 4. Hib Vaccine Product Picture
Figure 5. Meningococcal Vaccine Product Picture
Figure 6. Pneumococcal Vaccine Product Picture
Figure 7. Others Product Picture
Figure 8. Global Vaccine Conjugate Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Vaccine Conjugate Market Share by Application in 2022 & 2029
Figure 10. Children
Figure 11. Adult
Figure 12. Vaccine Conjugate Report Years Considered
Figure 13. Global Vaccine Conjugate Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Vaccine Conjugate Revenue 2018-2029 (US$ Million)
Figure 15. Global Vaccine Conjugate Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Vaccine Conjugate Revenue Market Share by Region (2018-2029)
Figure 17. Global Vaccine Conjugate Sales 2018-2029 ((K Doses)
Figure 18. Global Vaccine Conjugate Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Vaccine Conjugate Sales YoY (2018-2029) & (K Doses)
Figure 20. US & Canada Vaccine Conjugate Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Vaccine Conjugate Sales YoY (2018-2029) & (K Doses)
Figure 22. Europe Vaccine Conjugate Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Vaccine Conjugate Sales YoY (2018-2029) & (K Doses)
Figure 24. China Vaccine Conjugate Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Vaccine Conjugate Sales YoY (2018-2029) & (K Doses)
Figure 26. Asia (excluding China) Vaccine Conjugate Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Vaccine Conjugate Sales YoY (2018-2029) & (K Doses)
Figure 28. Middle East, Africa and Latin America Vaccine Conjugate Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Vaccine Conjugate Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Vaccine Conjugate in the World: Market Share by Vaccine Conjugate Revenue in 2022
Figure 31. Global Vaccine Conjugate Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 33. Global Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 34. Global Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 35. Global Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Vaccine Conjugate Revenue Share by Country (2018-2029)
Figure 41. US & Canada Vaccine Conjugate Sales Share by Country (2018-2029)
Figure 42. U.S. Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 45. Europe Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 46. Europe Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 47. Europe Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 48. Europe Vaccine Conjugate Revenue Share by Country (2018-2029)
Figure 49. Europe Vaccine Conjugate Sales Share by Country (2018-2029)
Figure 50. Germany Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 51. France Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 55. China Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 56. China Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 57. China Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 58. China Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 59. Asia Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 60. Asia Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 61. Asia Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 62. Asia Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 63. Asia Vaccine Conjugate Revenue Share by Region (2018-2029)
Figure 64. Asia Vaccine Conjugate Sales Share by Region (2018-2029)
Figure 65. Japan Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 69. India Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Vaccine Conjugate Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Vaccine Conjugate Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Vaccine Conjugate Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Vaccine Conjugate Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Vaccine Conjugate Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Vaccine Conjugate Sales Share by Country (2018-2029)
Figure 76. Brazil Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Vaccine Conjugate Revenue (2018-2029) & (US$ Million)
Figure 81. Vaccine Conjugate Value Chain
Figure 82. Vaccine Conjugate Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed